Table 1. Baseline demography and clinicopathological features (n = 38).
| Variable | Number (%) Median (range) |
|---|---|
| Age (years) | 54 (30–72) |
| Gender | |
| Male | 20 (53%) |
| Female | 18 (47%) |
| ALK detection method | |
| IHC | 19 (50%) |
| Fluorescent in-situ hybridisation | 19 (50%) |
| Brain metastasis (n = 34) | |
| Absent | 19 (56%) |
| Present | 15 (44%) |
| CNS-directed therapy (n = 15) | |
| Surgery | 4 (27%) |
| Stereotactic radiosurgery | 2 (13%) |
| Surgery + stereotactic radiosurgery | 2 (13%) |
| Whole brain radiotherapy | 7 (47%) |
| Brain metastases at the time of lorlatinib (n = 37) | |
| Absent | 19 (51%) |
| Present | 18 (49%) |
ALK, anaplastic lyphoma kinase; CNS, central nervous system